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Microwell platforms are frequently described for the efﬁcient and uniformmanufacture of 3-dimensional
(3D) multicellular microtissues. Multiple partial or complete medium exchanges can displace micro-
tissues from discrete microwells, and this can result in either the loss of microtissues from culture, or
microtissue amalgamation when displaced microtissues fall into common microwells. Herein we
describe the ﬁrst microwell platform that incorporates a mesh to retain microtissues within discrete
microwells; the microwell-mesh. We show that bonding a nylon mesh with an appropriate pore size
over the microwell openings allows single cells to pass through the mesh into the microwells during the
seeding process, but subsequently retains assembled microtissues within discrete microwells. To
demonstrate the utility of this platform, we used the microwell-mesh to manufacture hundreds of
cartilage microtissues, each formed from 5  103 bone marrow-derived mesenchymal stem/stromal cells
(MSC). The microwell-mesh enabled reliable microtissue retention over 21-day cultures that included
multiple full medium exchanges. Cartilage-like matrix formation was more rapid and homogeneous in
microtissues than in conventional large diameter control cartilage pellets formed from 2  105 MSC each.
The microwell-mesh platform offers an elegant mechanism to retain microtissues in microwells, and we
believe that this improvement will make this platform useful in 3D culture protocols that require
multiple medium exchanges, such as those that mimic speciﬁc developmental processes or complex
sequential drug exposures.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).f Technology at the Trans-
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Cell behavior in 3-dimensional (3D) in vitro cultures can
fundamentally differ from that in 2D cultures [1]. Cells in 3D cul-
tures experience fewer physical restrictions, allowing them tomore
readily establish microenvironments with enhanced cellecell
communication, organization and production of extracellular ma-
trix (ECM) [2]. The common approaches used to generate 3D tissues
in vitro have been recently reviewed [3], and each has its own ap-
peal depending on the application. An increasingly favored 3D
culture approach in cancer cell biology, organoid culture and
cartilage tissue engineering is the formation of multicellular ag-
gregates, termed microtissues [1e5]. Microtissues have been
manufactured for decades by aggregating hundreds-to-thousandsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tissue culture vessels [1]. While often favored over conventional 2D
cultures, these relatively labor-intensive methodologies have
delayed the widespread adoption of 3D microtissue culture [1,3].
Recent technological advances and the commercial availability of
products that enable high throughput microtissue manufacture via
microﬂuidic-based hanging drop, micro-patterned surfaces or
microwell platforms are increasingly bringing 3D microtissue cul-
ture into mainstream practice [3].
Microtissues are appealing building blocks in tissue engineering
applications [3,4,6e8], including the manufacture of cartilage
microtissues from either mesenchymal stem/stromal cells (MSC)
[5] or articular chondrocytes [8]. The fundamental motivation for
using a microwell platform tomanufacture cartilagemicrotissues is
its capacity to reproducibly generate hundreds of uniform micro-
tissue building blocks. This is achieved either through forced ag-
gregation (centrifugation) or gravity settling of a cell suspension
into an array of microwells placed at the bottom of a larger tissue
culture well [9]. Once the cells have settled into discrete microwells
they generally amalgamate within a few hours, and then mature
into uniform cartilage microtissues over the subsequent culture
period [5,8]. Complete medium exchange is often required to feed
microtissues, to sequentially modify the exogenous signal micro-
environment, and/or to guide the appropriate development of
artiﬁcial cartilage tissue. Complete or even partial medium ex-
change can generate turbulence that is sufﬁcient to dislodge
microtissues from their individual microwells. While careful
manipulation can reduce the frequency of microtissue displace-
ment from microwells, cartilage microtissues have a propensity to
adhere to each other making them particularly challenging to cul-
ture using conventional microwell systems. This challenge is
exasperated when cultures are scaled into larger 6-well formats or
when multiple full medium exchanges are required. Dislodged
microtissues that accumulate in individual microwells tend to
merge into single tissues of uncontrolled size and geometry. This
variability diminishes the advantages of microwell systems, and
hampers the development of complexmedium exchange protocols.
Such protocols are likely required to generate hyaline cartilage from
MSC [11] or to manufacture cartilage microtissues on a large-scale
for clinical applications.
To address the above problems in cartilage microtissue manu-
facture, and to more generally improve upon the current microwell
platforms, we have developed a microwell platform with a nylon
mesh ﬁxed over the microwell openings, which we term the
“microwell-mesh”. The pores in the mesh are sufﬁciently large to
permit single cells to pass into the microwells. Once the cells
aggregate within the microwell, the resulting microtissue is too
large to pass back out through the mesh and remains trapped
within its discrete microwell. Herein we outline the microwell-
mesh fabrication methodology, and describe the application of
the microwell-mesh innovation to high throughput cartilage
microtissue manufacture. Speciﬁcally, we contrast the differentia-
tion and cartilage-like matrix formation of bone marrow-derived
MSC either aggregated into singular pellets of 2  105 MSC each
(control pellet cultures) or into hundreds of microtissues of
approximately 5  103 MSC each (cartilage microtissues) using the
microwell-mesh platform.
2. Methods
2.1. Microwell mold manufacture
The microwell surfaces were produced using a reverse tem-
plating process. An acrylic sheet with a pyramidal array was pur-
chased from Mulford Plastics (Australia), and served as the initialmold. Each pyramidal well on the acrylic sheet was 2 mm  2 mm
square, by 0.8 mm deep. A negative impression was created by
casting a 10 mm thick layer of polydimethylsiloxane (PDMS, Syl-
gard184; Dow Corning, Midland MI, USA) over the acrylic surface.
The PDMS was allowed to cure for 1 h at 80 C and then removed
from the acrylic mold and incubated at 80 C for an additional 72 h.
Incorporation of the additional curing time crystalizes the PDMS
surface sufﬁciently to prevent bonding during the double casting of
PDMS [12]. The PDMS negative impression was then used to
generate a 10 mm thick PDMS positive impression of the original
acrylic surface. The positive PDMS impression layer was cured for
60 min at 80 C, and then peeled from the PDMS negative
impression. Finally, a reusable negative template surface was
formed using a hot press (POWER TEAM hydraulic heat press) at
160 C for 15 min to press the ﬁnal PDMS surface template into
sheets of polystyrene. Polystyrene sheets were cut from 500 cm2
cell culture dishes (Corning, NY USA). The hot pressed polystyrene
negatives were then used to generate sheets of PDMS having the
microwell surface pattern.
2.2. Microwell and microwell-mesh fabrication
Microwell-mesh fabrication is summarized schematically in
Fig. 1A. In brief, a 3 mm deep layer of PDMS was poured on the
polystyrene negative template and cured for 60 min at 80 C. Discs
were punched from the PDMS sheet using a 35mm diameter Priory
wad punch (Amazon.com), producing discs that ﬁt snugly into 6-
well plates. Square pieces (4 cm  4 cm) cut out from a sheet of
nylon (6/6) mesh (36 mm square pore openings, part number: CMN-
0035, Amazon.com) were bonded to the open face of the microwell
discs using silicone glue (Selleys Aquarium Safe, Padstow, New
South Wales). To apply a thin layer of silicone glue over the
microwells, a foam biopsy pad (Fisherbrand) was saturated with
silicone glue and excess glue dabbed off onto a waste surface prior
to gently dabbing the top of the microwell discs. The square of
nylon mesh was applied over top and pressed down to ensure
adequate contact with the top edges of the PDMS microwells. The
silicone glue ﬁxing the nylon mesh was cured overnight at room
temperature, and the excess meshwas then trimmed from the edge
of the microwell disc. A small dab of silicone glue was used to an-
chor the microwell disc insert in a well of a 6-well plate (Cat#:
CLS3516, Corning). The silicone glue anchoring the microwell disc
inserts was cured for 60 min on an 80 C hot plate. PDMS was
selected for the manufacture of the base microwell platform as
PDMS rapid fabrication is inexpensive, versatile, and has been
successfully used to manufacture microwells in similar studies
[4,8]. Nylon (6/6) was selected for use in themesh as nylon is a non-
toxic biocompatible material commonly used in clinical applica-
tions including formation of gastrointestinal segments, vascular
grafts, and sutures [13]. Critically, nylon (6/6) meshes with tailored
pore sizes can be readily purchased from commercial vendors.
2.3. Microwell-mesh characterization via micro-computed
tomography (mCT)
Microecomputed tomography (mCT) was used to characterise
the shape and dimension of the cavities in the microwell-mesh. To
enhance the contrast, the microwell-mesh ﬁbers and surface were
sputter coated with gold (Leica EM SCD005 sputter coater). All mCT
workﬂows were performed on the mCT subsystem of an Inveon
Multimodality PET-mCT (Siemens, Munich Germany) system
equipped with a variable focal spot X-ray source. 720 projection
images were acquired in a 360 rotation around the sample, with a
ﬁeld of view of 1024 1152 pixels. The imaging protocol for the
standard detector used X-ray settings of 80 kVp at 0.5 mA with a
Fig. 1. (A) Fabrication of microwell-mesh inserts. PDMS sheets with microwells 2 mm  2 mm square, by 0.8 mm deep were cast on a polystyrene mold. Discs 35 mm in diameter
were punched from the sheets. Nylon mesh was bonded to the top of the microwell disc creating the microwell-mesh system. The nylon mesh was then trimmed to align with the
edge of the PDMS disc, and the discs were anchored in 6-well plates using silicone glue. (B) Micro-computed tomography of the microwell-mesh shows the shape and dimensions of
the microwells. Microwells were conﬁrmed to be 2 mm  2 mm  0.8 mm deep. The nylon mesh was bonded to the top of each microwell forming sealed discreet culture
microwells. (C) Cells were pelleted through the nylon mesh into microwells via forced aggregation. Cells that had amalgamated into microtissues were too large to pass back
through the nylon mesh and were retained in discreet microwells.
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were acquired with a bin factor of 2 and were reconstructed using
the Feldkamp algorithm with no down sampling, resulting in im-
ages with pixels of 36 mm in each dimension. All image processing
and analysis was performed on the Inveon Research Workplace 4.2
software package.
2.4. Microwell-mesh sterilization
The microwell-mesh inserts were sterilized with 70% ethanol/
water. To ensure that all surfaces contacted the sterilizing solution,
4 mL of 70% ethanol was aliquoted into each well and then the
plate was centrifuged at 2000  g for 2 min. The plate was then
entirely submerged in 70% ethanol and incubated for 60 min at
room temperature. Following incubation in ethanol, the wells
were washed twice with 4 mL of PBS (Life Technologies, Mulgrave,
Australia). During the second rinse the plates were again centri-
fuged at 2000  g for 2 min to ensure that the PBS had displaced
the ethanol. The wells were rinsed a third time with 4 mL of PBS
and left to soak overnight to elute any residual ethanol from the
PDMS. If the plates were to be stored for future use, sterile water
was used instead of PBS and the plates were dried. Immediately
prior to use, the microwell-mesh inserts were washed with a
sterile solution of 5% Pluronic (F-127 Pluronic, Sigma Aldrich,
Castle Hill, Australia) in PBS. Pluronic adsorbs onto the PDMS
surface, rendering it non-adhesive and thereby promoting cell
aggregation [4,9]. The plate was centrifuged at 2000  g for 2 min
to ensure that the Pluronic solution contacted all surfaces and that
any bubbles were displaced from the microwells. The Pluronic was
permitted to adsorb for at least 5 min before rinsing with 4 mL of
PBS.
2.5. Mesenchymal stem/stromal cell (MSC) isolation and culture
MSC isolation and characterization was performed similarly to
previously described [5]. Bone marrow aspirates (BMA) were
collected from the iliac crest of fully informed and consenting
healthy volunteer donors. The Mater Health Services Human
Research Ethics Committee and the Queensland University ofTechnology Human Ethics Committee approved aspirate collection
(Ethics number: 1541A). A single puncture into the iliac crest was
performed to collect 20 mL of BMA. BMA samples were diluted 1:1
with 2 mM EDTA/PBS and overlaid onto 15 mL Ficoll Paque Plus (GE
Healthcare). The solution was centrifuged at 400  g for 30 min.
Interface cells were collected, washed and resuspended in low
glucose DMEM (DMEM-LG; Gibco) containing 10% fetal bovine
serum (FBS; Life Technologies), 10 ng/mL ﬁbroblast growth factor-1
(FGF-1; Peprotech, Israel), and 100 U/ml penicillin/streptomycin
(PenStrep; Gibco). The cells collected from the Ficoll separation of
individual aspirates were seeded into three T175 ﬂasks (Becton
Dickinson, New Jersey USA), with 35 mL of culture medium per
ﬂask. The cultures were incubated overnight in a 20% O2 and 5% CO2
atmosphere at 37 C. The next day, cultures were enriched for
plastic adherent cells by aspirating off the medium containing non-
adherent cells, and replacing with fresh culture medium. The cul-
tures were then transferred to a reduced-O2 incubator with a 2% O2
and 5% CO2 atmosphere at 37 C. Adherent cells were passaged
when the monolayer reached 80% conﬂuency using 0.25% Trypsin/
EDTA (Gibco). The cells were re-seeded at ~1500 cells per cm2 in
new culture ﬂasks.
2.6. MSC ﬂow cytometry characterization of MSC
Expanded cells were characterized for their expression of CD45,
CD34, CD90, CD73, CD105, CD44, CD146, CD271 and HLA-DR
(Miltenyi Biotec). The cells were stained with ﬂuorescently conju-
gated antibodies as per manufacturer's instructions and analyzed
on a BD LSRII ﬂow cytometer (Becton Dickinson). Data was
analyzed using FlowJo software (TreeStar, Oregon, USA).
2.7. Chondrogenic induction culture
To induce chondrogenic differentiation, MSC were resuspended
in DMEM-high glucose (DMEM-HG; Gibco) containing, 1 Gluta-
Max (Gibco), 10 ng/mL TGF-b1 (PeproTech, Rocky Hill, NJ), 100 nM
dexamethasone (Sigma), 200 mM ascorbic acid 2-phosphate
(Sigma), 100 mM sodium pyruvate (Gibco), 40 mg/mL L-proline
(Sigma), 1% ITS-X (Gibco) and 100 U/ml PenStrep (Gibco).
Fig. 2. (AeD) Microtissues increased in size during culture. (E) Following 21 days of
culture, after 10 full medium exchanges, microtissues had been retained in discreet
microwells by the nylon mesh. (F) Microwell-mesh inserts were removed from the
well plates, and the nylon mesh was peeled from the PDMS insert. Most microtissues
remained loosely bound to the mesh as shown in the image. (G&H) Cells were dis-
lodged from the nylon mesh using a cell scraper and collected into a 15 mL tube
containing PBS. Images AeD scale bar ¼ 1 mm.
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Control pellet cultures were prepared in 96-deep well V-bottom
plates (Cat#: 3960, Corning) by suspending 2  105 MSC in 1 mL of
chondrogenic induction medium. MSC were pelleted in the V-
bottom plates by centrifuging the plate at 500  g for 3 min. In-
duction cultures were maintained in a 2% O2 and 5% CO2 atmo-
sphere at 37 C. A half-volume medium exchange was performed
every second day.
2.9. Cartilage microtissue manufacture in the microwell-mesh
The mechanism of depositing and retaining cells in the
microwell-mesh is a key innovation in the current device. As shown
schematically in Fig. 1C, cells can be directed through the 36 mm
openings of the nylon mesh using centrifugation (forced aggrega-
tion [9]). Once the pelleted cells amalgamate, the resulting micro-
tissues are too large (diameter >36 mm) to pass back through the
pores of the nylon mesh, thereby retaining the microtissues in
discreet microwells covered by the nylon mesh. All microwell-
mesh cultures were performed in 6-well plates with 4 mL total
chondrogenic induction medium per well. Prior to the addition of
cells to the culture wells, 3 mL of cell-free chondrogenic induction
medium was added to each well and the plate was centrifuged at
2000  g for 2 min. This step was included to ensure bubbles were
eliminated from the microwell-mesh prior to the addition of the
cell inoculum. The cell inoculum was a 1 mL volume containing
1.2  106 MSC. As the microwell-mesh platform contained 240
microwells, this MSC concentration enabled the formation of
microtissues containing ~5  103 cells each. MSC were pelleted in
the microwell-mesh platform by centrifuging the plate at 500  g
for 3 min. Induction cultures were maintained in a 2% O2 and 5%
CO2 atmosphere at 37 C, with full-volume medium exchange
performed every 2 days.
2.10. Microtissue harvest from the microwell-mesh
Microtissues were harvested from the microwell-mesh as
shown schematically in Fig. 2. The microwell-mesh inserts were
removed aseptically from the well plates using sterile forceps. The
mesh was then gently peeled from the microwell insert using for-
ceps. Nearly all of the cartilage microtissues remained loosely
attached to the mesh. Microtissues were gently scraped off the
mesh into a petri dish using a cell scraper (Cat#: 3011, Corning) and
then collected into a 15 mL tube using PBS to resuspend.
2.11. Glucose uptake and lactic acid production
At each medium exchange time point, a portion of the spent
medium was collected and stored at 80 C for subsequent quan-
tiﬁcation of glucose and lactic acid concentration. Glucose and
lactic acid analysis was performed by a pathology laboratory (Mater
Hospital, Brisbane). Speciﬁc cellular uptake rates were determined
based on the cell numbers used to initiate each culture and the
glucose and lactic acid concentration at each medium exchange
interval.
2.12. Glycosaminoglycan (GAG) quantiﬁcation
GAG content was assessed in microtissues and pellets harvested
on day 7, 14 and 21, as well as in media samples collected during
media exchanges. All samples were stored at 80 C until analysis.
Microtissues or pellets were digested overnight at 60 C using
1.6 U/mL papain (Sigma). DNA and GAG quantiﬁcation was per-
formed immediately after digestion (without freezing samples).DNA content was determined using a PicoGreen assay kit (Life
Technologies). GAG from tissue digests and medium were quanti-
ﬁed using the 1,9-dimethymethylene blue (DMB, Sigma) assay as
described previously [5]. Chondroitin sulfate sodium salt from
shark cartilage (Sigma) was used to generate a standard curve for
this assay. Data sets were analyzed for statistically signiﬁcant dif-
ferences in GAG levels between control cartilage pellets and
microtissues at each time point using a two-tailed unpaired t-test,
with signiﬁcance indicated when P < 0.05.2.13. Quantitative real-time RT-PCR (qRT-PCR)
RNAwas isolated from control cartilage pellets and microtissues
using the RNeasy Mini Kit (Qiagen) as per the manufacturer's in-
structions. Samples were subject to on-column DNase I digestion at
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reverse transcribed using SuperScript III First-Strand Synthesis
System for RT-PCR (Invitrogen) as per the manufacturer's in-
structions. For control cartilage pellets, a ﬁnal amount of 60 ng of
input RNA was achieved by pooling equal amounts of 2 indepen-
dently generated pellets. 1 mL of the resultant cDNA product was
used in a 20 mL qRT-PCR mastermix containing 1 SYBR Green PCR
Master Mix (Applied Biosystems) and 200 nM each of the forward
and reverse primers. 5 mL triplicate reactions were run in 384 well
plates on a Viia7 Real Time PCR System (Applied Biosystems) as
technical replicates. Run parameters were a single initial cycle of
50 C for 2 min and 95 C for 10 min, followed by 40 cycles of 95 C
for 15 s and 60 C for 1 min. Speciﬁcity of products was conﬁrmed
by melt curve analysis. Three housekeeping genes (GAPDH, RPLPO
and RPL13A) were analyzed for each sample. Relative gene
expression for day 7 pellets was determined using GAPDH, while
RPL13A was deemed the most stable housekeeping gene for the
normalization of day 14 and day 21 samples. Data sets were
analyzed for statistically signiﬁcant differences in gene expression
levels between control cartilage pellets and microtissues at each
time point using a two-tailed, unpaired t-test with conﬁdence in-
tervals set at 95%. Primer sets used are detailed in Table 1. Previ-
ously published primers were as follows: GAPDH, ACAN, COL1A1,
COL2A1 [14]; RPL13A, RPLPO and COL10A1 [15]; RUNX2 [16].
Primers for SOX9 were designed using Primer3Plus software [17].
2.14. Artiﬁcial cartilage defect model, ﬁll and subcutaneous
implantation
Artiﬁcial cartilage defect models were prepared from bovine
tissue, ﬁlled with engineered control pellets or microtissues, sealed
with ﬁbrin glue, and then incubated subcutaneously in NOD/SCID
mice. Similar cartilage defect models have been described previ-
ously [18]. While such models are not true representations of
cartilage defects, they do provide reference bone/cartilage tissues
and an indication of the capacity of the ﬁll tissue to bond with
native tissue(s). In our study, bovine legs, including the kneeTable 1
Primers used for qRT-PCR.
Gene Sequence (50e30) Amplicon size (bp)
GAPDH 70
forward ATGGGGAAGGTGAAGGTCG
reverse TAAAAGCAGCCCTGGTGACC
ACAN 85
forward TCGAGGACAGCGAGGCC
reverse TCGAGGGTGTAGCGTGTAGAGA
COL1A1 83
forward CAGCCGCTTCACCTACAGC
reverse TTTTGTATTCAATCACTGTCTTGCC
COL2A1 79
Forward GGCAATAGCAGGTTCACGTACA
Reverse CGATAACAGTCTTGCCCCACTT
RPL13A 101
Forward GGCTTTCCTCCGCAAGCGGAT
Reverse GCAGCATACCTCGCACGGTCC
RPLPO 137
Forward TGTGGGCTCCAAGCAGATGCA
Reverse GCAGCAGTTTCTCCAGAGCTGGG
COL10A1 132
Forward ACTCCCAGCACGCAGAATCCA
Reverse TGGGCCTTTTATGCCTGTGGGC
RUNX2 133
Forward GGAGTGGACGAGGCAAGAGTTT
Reverse AGCTTCTGTCTGTGCCTTCTGG
SOX9 102
Forward ACTCCTCCTCCGGCATGAG
Reverse GCTGCACGTCGGTTTTGGcapsules, were purchased from G.E. Mallan Bulk Meats Fairﬁeld
(Australia). Plugs of cartilage and bone were drilled out from the
knees using a 10 mm coring bit, and full thickness cartilage defects
drilled out of the plug using a 3.5mmdrill bit (Fig. 7). Defect models
were repeatedly washed in PBS to remove debris, and then steril-
ized in 70% ethanol/water for 2 h. Sterilized defect models were
washed three times with PBS and then left to soak in PBS overnight
to elute any remaining ethanol. Defect models were then frozen
until time of use. Prior to loading the defect models with control
cartilage pellets or microtissues, the models were soaked in
chondrogenic induction medium for 20 min. Control pellets or
microtissues that had been cultured in chondrogenic induction
medium for 2 weeks were loaded into the defect sites using a
transfer pipette (Sarstedt AG & Co. Sarstedt, Germany). The top of
the defect was sealed using ﬁbrin glue (Tisseel™, Baxter) by ﬁrst
dripping 20 mL of the ﬁbrinogen solution over the defect, followed
by 20 mL of thrombin solution. Defect models were then submerged
in 1 mL of chondrogenic induction medium (in a 24-well plate) and
incubated overnight in a 2% O2 and 5% CO2 atmosphere at 37 C.
After 24 h, the defect models were implanted subcutaneously into
NOD/SCID mice. The University of Queensland and the Queensland
University of Technology animal ethics committees approved this
procedure. Two defect models were placed subcutaneously onto
the back of each 8-week-old female mouse. The tissues were
allowed to mature in vivo for 8 weeks at which point the animals
were euthanized and the tissues explanted for analysis.
2.15. Histology and immunohistochemistry
Pellets and cartilage microtissues were ﬁxed in 4% para-
formaldehyde (PFA) for 30 min and frozen in Tissue-Tek OCT
compound (Sakura Finetek) on days 7, 14 and 21. Samples were
cryosectioned at 7 mm and collected onto poly-lysine coated slides
(Thermo-Scientiﬁc, Waltham, MA) and frozen until further pro-
cessing. Thawed sections were ﬁxed for 20 min with 4% PFA and
washed with PBS.
Explanted defect models were ﬁxed in 4% PFA for 24 h and
decalciﬁed with decalciﬁcation solution (10% EDTA, 0.07% glycerol,
PBS, pH 7.4) at 4 C on a rocker, replacing the solution each day.
Once the bone was pliable, the defect constructs were washed with
PBS. The constructs were dehydrated in a graded series of ethanol
and parafﬁn-embedded. 5 mm sections were cut in the sagittal
plane. Sections were deparafﬁnized with xylene and rehydrated
through a graded series of ethanol, and then stained with Alcian
blue (SigmaeAldrich) or Safranin-O (SigmaeAldrich) to detect
glycosaminoglycan (GAG) and with Nuclear Fast Red (Sigma-
eAldrich) to detect nuclei.
Immunoﬂuorescence (IF) staining was performed for collagen
type I (Col I), collagen type II (Col II) and collagen type X (Col X). For
Col II and Col X, sections were treated with chondroitinase (0.25 U/
mL, Sigma) and hyaluronidase (2 U/mL, Sigma) for 60 min at 37 C.
For Col I, tissue sections were treated with Proteinase K (2.0 mg/mL)
for 15 min. Sections were permeabilized with 0.1% Triton X-100 for
5 min and blocked with 10% normal goat serum (Invitrogen) for
30 min at room temperature. The sections were then stained with
primary antibodies (all from Abcam) raised against Col I (1:800;
Cat# ab6308), Col II (1:100; Cat# ab34712) and Col X (1:100; Cat#
ab58632) in 1% BSA/PBST (PBS þ 0.1% Tween 20) at 4 C overnight.
Secondary antibody detection was performed using Alexa Fluor
568-conjugated goat anti-rabbit IgG and Alexa Fluor 488-
conjugated goat anti-mouse IgG (both from Molecular Probes) at
1:1000 in 1% BSA/PBS for 60 min at room temperature in the dark.
After each staining step, unbound antibodies were washed 3 times
with PBS for 5 min each. Nuclei were counterstained with DAPI
(Molecular Probes) for 5 min at room temperature in the dark.
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lecular Probes) and examined with an Olympus BX61 ﬂuorescence
microscope. Negative controls were prepared the same as above,
but without primary antibodies.
3. Results
3.1. Microwell-mesh characterization via micro-computed
tomography (mCT)
mCT characterization of the microwell-mesh surface and cross-
section demonstrated that the dimensions of the microwell mold
were reliably cast into the PDMS negative. The nylon mesh sealed
each individual microwell, forming individual v-bottommicrowells
that were 2 mm  2 mm square 0.8 mm deep.
3.2. MSC ﬂow cytometry characterization
As shown in Supplementary Fig. 1, MSC stained negative for
hematopoietic markers CD45 and CD34 and positive for MSC
markers CD90, CD44, CD73, CD105, CD146. Approximately 12% of
cells were CD271 positive.
3.3. Microwell-mesh tissue retention over extended culture
Fig. 2AeD shows the growth of the cartilage microtissues in the
microwell-mesh over the ﬁrst 14 days culture period prior to in vivo
implantation. Cartilage microtissues were retained within the
microwell-mesh over the 21 day culture period (Fig. 2E). No
microtissues were displaced from microwells despite 10 full me-
dium exchanges. When the mesh was peeled away from the
microwell platform (Fig. 2F), nearly all of themicrotissues remained
loosely attached to the mesh and were easily harvested by gentle
scraping (Fig. 2G&H). The image of the mesh at day 21 (Fig. 2E&F)
illustrates the uniformity of the microtissues manufactured using
the microwell-mesh platform.
3.4. Glucose uptake and lactic acid production
Microwell-mesh cultures were initiated with 1.2  106 cells in
4 mL of medium, and control pellet cultures were initiated with
2  105 cells in 1 mL of medium. In order to provide similar rates
of medium exchange, full-volume medium exchanges were per-
formed on microwell-mesh cultures and half-volume medium
exchanges were performed on control pellet cultures every 2
days. The measured glucose consumption and the accumulation
of lactic acid between medium exchanges is shown graphically in
Fig. 3A and C, respectively. The microwell-mesh cultures exhibi-
ted more rapid ﬂuctuation in medium glucose and lactic acid
content between medium exchanges. The glucose concentration
in the microwell-mesh cultures declined from ~22 mM to
~10 mM at each medium exchange, and there was a corre-
sponding increase in lactic acid concentration to approximately
25 mM. Fig 3B shows that the speciﬁc cellular glucose uptake
rates in the microwell-mesh cultures and control pellet cultures
were 7.28  1010± 9.1  1011 mmol/cell/hour and
1.17  1010± 2.5  1011 mmol/cell/hour, respectively. This data
indicates that the speciﬁc cellular glucose uptake rates in the
microwell-mesh cultures were approximately 6.2-fold greater
than in the control pellet cultures. Similar glucose uptake rates
have been reported for chondrocytes in cartilage [19], and very
similar rates (3.57  1010 mmol/cell/hour) have been reported
for pellet cultures formed from 2  105 MSC each [20].
Fig 3D shows that the speciﬁc cellular lactic acid production
rates in the microwell-mesh cultures and control pellet cultureswere 1.60  109± 2.9  1011 mM/cell/hour and
2.34 1010± 4.9 1011 mM/cell/hour, respectively. This suggests
that the speciﬁc cellular lactic acid production rates in the
microwell-mesh culture were ~6.8-fold greater than in the control
pellet cultures. The ~2:1 ratio of glucose consumption to lactic acid
production indicates that cells in both culture systems were largely
respiring anaerobically.
3.5. GAG secretion proﬁles
DNA quantity was used as an indirect measure of cell number at
various time-points. We observed a reduction in DNA in both the
control pellet cultures and microwell-mesh cultures. The DNA
content in the cultures dropped between culture initiation and day
7, after which the DNA content remained stable in all cultures
(Fig. 4A). Total cell secreted GAG was quantiﬁed using a medium
sample collected at each media exchange interval. The quantity of
GAG in the cartilage microtissue culture medium was greater than
in the control pellet culture medium at all medium exchange time
points (Fig. 4B). The quantity of GAG secreted by the microwell-
mesh cultures increased rapidly over the ﬁrst 6 days of culture,
stabilized at 35e45 mg GAG/mg DNA during the second week of
culture, and then dropped marginally to ~30 mg GAG/mg DNA over
the third week of culture. By contrast the control pellet cultures
secreted ~10 mg GAG/mg DNA at day 6, with this value increasing to
~17 mg GAG/mg DNA over the second week, after which it stabilized
at ~15 mg GAG/mg DNA over the third week of culture.
3.6. GAG retained in tissues
The quantity of GAG retained in tissues was standardized to the
corresponding DNA content at the point of harvest (Fig. 4A). Tissue-
retained GAG per mg DNA in the microwell-mesh cultures always
exceeded the tissue-retained GAG in control pellet cultures
(Fig. 4C). The relative tissue-retained GAG per mg DNAwas 7.8-fold,
1.7-fold and 1.3-fold greater in the microwell-mesh culture than in
the control pellet culture at day 7, day 14 and day 21, respectively.
3.7. Chondrogenic and hypertrophic gene expression
In vitro cultured cartilage tissues were analyzed for expression
of genes related to both chondrogenesis and hypertrophy (Fig. 5). In
the ﬁrst two weeks of culture, microwell-mesh tissues tended to
express higher levels of the chondrogenic genes SOX9, collagen II
and aggrecan, as compared to control pellet tissues at similar time
points. These differences were only statistically signiﬁcant for
collagen II at days 7 and 14, and for aggrecan at day 7. By day 21 this
trend appeared to be reversing with little difference detected be-
tween the two culture conditions for collagen II and aggrecan, and
signiﬁcantly greater levels of SOX9 in the control pellet tissues,
compared to the microwell-mesh tissues. Markers of hypertrophy,
RUNX2 and collagen X, were expressed at signiﬁcantly higher levels
in microwell-mesh tissues compared to control pellet culture tis-
sues at all time points with the exception of RUNX2 at day 7.
Collagen I, a marker of ﬁbrocartilage or bone formation, was also
detected at signiﬁcantly higher levels in the microwell-mesh
cartilage tissues at day 7 and 14, but not at day 21 when
compared to control pellet culture tissues.
3.8. In vitro histology and matrix characterization
Histological sections from cartilage tissue produced in the
microwell-mesh and control pellet cultures at day 7, 14 and 21 are
shown in Fig. 6. Alcian blue staining shows that the GAG content
was greater andmore evenly distributed in cartilagemicrotissues at
Fig. 3. Glucose uptake and lactic acid production rates were estimated following the quantiﬁcation of glucose and lactic acid concentrations in the medium at medium exchange
intervals. (A&C) Glucose and lactic acid concentrations in remaining in medium samples taken at exchange intervals were quantiﬁed. (B&D) The speciﬁc cellular uptake of glucose
and lactic acid production rates were estimated based on the concentrations shown in captions A&C and the cell number used to initiate the control pellet and microwell-mesh
cultures, respectively (mean ± SD, n ¼ 6, P < 0.05).
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distribution of Alcian blue staining in the cartilage microtissues
persisted at day 14 and day 21. By contrast, the intensity of Alcian
blue staining of the control cartilage pellets was very weak at day 7,
but increased substantially over the next two weeks (day 14 and
day 21), with staining intensity matching that of the microtissues
by day 21.
The cores of control pellet cartilage tissues at day 7 were
completely devoid of collagen II staining. In contrast, cartilage
microtissues expressed collagen II throughout the entirety of the
majority of pellets, with evidence of increased expression at the
periphery. By day 14 both control cartilage pellets and cartilage
microtissues expressed collagen II throughout the tissues, with
distinctly stronger staining at the periphery. This pattern of
expression was maintained at day 21 for both the control pellet
tissues and the cartilage microtissues.
Similar to collagen II expression, collagen X staining was absent
in the core of control pellet tissues at day 7. Cartilage microtissues
at day 7 showed uniform collagen X staining with no evidence of
increased levels at the periphery of the tissues. At days 14 and 21
the pattern of collagen X expression was reminiscent of that
observed for collagen II expression for both tissue types, with
expression throughout the tissues and more intense staining at the
periphery.
Collagen I was expressed throughout the cartilage microtissues
at day 7 with a consistently increased level of expression at the
outer edges of the tissues. As with the other collagens, day 7
control cartilage pellets were completely devoid of staining in the
central zone with expression restricted to the periphery of the
tissues. Under both culture conditions, there was evidence of
more uniform expression throughout the tissues at day 14. By day
21 collagen I expression was becoming increasingly restricted to
the periphery of both cartilage microtissues and control pellet
cartilage tissues.3.9. In vivo histology and matrix characterization
Control cartilage pellets and cartilage microtissues that had
been cultured in chondrogenic induction medium for 14 days were
used to ﬁll cartilage defect models and implanted subcutaneously
into NOD/SCID mice for 8 weeks. Harvested explants were
sectioned and stained to characterize the ﬁll of the cartilage defect
model and the matrix distribution in the matured cartilage tissues
(Fig. 7). As expected, the smaller cartilage microtissues packed into
defects more efﬁciently, compared to the larger diameter control
cartilage pellets. Both the control cartilage pellets and cartilage
microtissues integrated with the native tissue of the defect model,
requiring signiﬁcant force to remove them from the defect site.
Individual pellets also bonded together during the in vivo incuba-
tion period, producing as a single unit if removed from the defect
site.
Upon dissection it was evident that multiple cartilage tissues
had bonded together during the in vivo incubation period. However,
both the control pellet tissues and the cartilage microtissues
retained discrete pellet morphology with central areas of each
pellet displaying high levels of proteoglycans and signiﬁcant GAG
content (Fig. 7 Safranin-O and Alcian blue respectively). High levels
of the chondrogenic marker collagen II were detected in both the
native tissue of the defect model and in the engineered tissues. This
was offset by the presence of collagen I staining predominantly at
the periphery of the control cartilage pellets and cartilage micro-
tissues indicating the formation of ﬁbrocartilage or bone-like
tissue.
4. Discussion
Cartilage pellet cultures were ﬁrst described in 1998 [21] and
traditionally involve the aggregation of 1e5  105 MSC in chon-
drogenic inductionmedium. ThisMSC chondrogenic differentiation
Fig. 4. DNA in harvested tissues, and GAG secretion into medium and GAG retained in
Microwell-mesh and pellet cultured tissues. (A) Total DNA content (mg) detected for
each culture was proportional to the initial number of cells seeded. Control pellet
cultures were initiated with 2  105 cells each, while microwell-mesh cultures were
initiated with 1.2  106 cells each. (B) The GAG secreted by cultures maintained
microwell-mesh as a function of the tissue DNA content was greater than in the control
cartilage pellet cultures. (C) The quantity of retained GAG per mg of DNA was greater in
microwell-mesh cartilage microtissues than in control pellet cartilage tissues at each
time point (mean ± SD, n ¼ 6, P < 0.05).
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gold standard in the ﬁeld. While reasonably effective, the resulting
large diameter (2e3 mm) pellets form steep radial diffusion gra-
dients [5]. Radial heterogeneity in both cell phenotype and matrix
composition is common [22,23] and a necrotic core is sometimes
observed [24].
We have previously manufactured thousands of smaller diam-
eter cartilage microtissues using the Aggrewell™ (StemCell Tech-
nologies) [5] and our own in-house fabricated microwell platform
[8]. The reduced diameter enhanced metabolite and signal mole-
cule diffusion in the resulting microtissues, enabled the formationof more homogenous tissue, and signiﬁcantly enhanced chondro-
genic differentiation [5]. While this demonstrated the advantages
of cartilage microtissues over traditional cartilage pellets, inte-
grating more sophisticated medium exchange and scale-up pro-
tocols was frequently thwarted by the displacement of microtissues
from their original discrete microwells. Displaced microtissues
were either lost from culture or redistributed into adjacent
microwells and amalgamatedwith othermicrotissues. To overcome
this technical barrier, we developed the microwell-mesh platform.
In this paper we used the microwell-mesh to manufacture micro-
tissues from 5  103 MSC each. This cell number was selected
through preliminary experimentation that demonstrated that
cartilage microtissues of this size grew to ﬁll the
2 mm  2 mm  0.8 mm microwells (as shown in Fig. 2) over the
given culture period, and that microtissues of this size could be
easily harvested for downstream processing. Today, soft lithog-
raphy and other industrial fabrication methods make the manu-
facture of microwell-mesh platforms with a range of microwell
dimensions readily achievable. The size of resultant microtissues
can be readily controlled by tailoring the size of the microwells or
the number of cells loaded in the microwells. Smaller microwells
are more suitable for the manufacture of smaller microtissues,
described in previous papers [4,5,7,8]. The platform designed and
tested here is suitable for producing microtissues starting from cell
numbers of >1000 cells per microtissue or microtissues that may
grow substantially during the culture period from fewer cells. The
suitability of a speciﬁc shape/size of microwell system and the cell-
to-microwell seeding ratio should be considered a critical experi-
mental design consideration, as these factors can affect culture
outcomes, including including cell differentiation [25]. The
microwell-mesh dimensions described here are ideal for the for-
mation and growth of MSC differentiated cartilage microtissues
from 5 103 cells each. Attachment of a nylonmesh to enclose each
microwell facilitated the retention of microtissues in discrete
microwells during numerous full-medium exchanges over a 21-day
culture period (Fig. 2). The mature microtissues were easily har-
vested by peeling themesh from the PDMSmicrowell insert (Fig. 2).
Glucose uptake and lactic acid production rates were approxi-
mately 6-fold greater for cells cultured as microtissues in the
microwell-mesh than cells in control pellet cultures (see Fig 3).
These highly metabolically active cultures may beneﬁt from more
frequent media exchanges that could be facilitated by a perfusion
feeding system. Because the mesh effectively retains microtissues
within discrete microwells, this platform is well suited for inte-
grationwith perfusion technologies. In this proof-of-concept study,
we fully exchanged the 4 mL medium volume in microwell-mesh
cultures every 2 days. Glucose turnover in control pellet cultures
was comparatively minute, suggesting that the dimensions of the
macroscopic pellet limit metabolism. Similarly, the increase in
metabolic activity observed in the microwell-mesh cultures cor-
relates with the observed accelerated chondrogenic differentiation
and matrix development discussed below.
The accumulation of GAG and aggrecan in engineered tissues is
associated with the early stages of MSC chondrogenesis [26].
Aggrecan is the primary proteoglycan in articular cartilage towhich
GAG side chains are linked, and these hybrid molecules are largely
responsible for the compressive stiffness properties of articular
cartilage [27,28]. Thus the rapid accumulation of GAG (Fig. 4B and
C) and the early upregulation of aggrecan gene expression (Fig. 5)
indicated accelerated chondrogenic differentiation in the
microwell-mesh cultures, relative to the larger diameter control
pellets. The comparatively low levels of GAG observed in the con-
trol pellets at day 7 (Fig. 4C) was consistent with Alcian blue his-
tological staining (Fig. 6 e day 7), which suggested that GAGmatrix
accumulationwas restricted to the periphery of these larger tissues.
Fig. 5. qRT-PCR analysis of cartilage tissue produced by control pellet culture and microwell-mesh culture methods. Increased expression of chondrogenic markers was accom-
panied by increases in markers of hypertrophy and ﬁbrocartilage formation in microwell-mesh cartilage tissues. Expression levels for day 7 samples are shown relative to GAPDH
and for day 14 and 21 samples relative to RPLPO (plotted as mean ± SD, n ¼ 3 for control pellet tissues and n ¼ 4 for microwell-mesh tissues, *** indicates P < 0.05).
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was supported by the more uniform collagen II matrix staining at
day 7 relative to the control cartilage pellets (Fig. 6). As with the
GAG proﬁle, collagen II staining was only detectable at the pe-
riphery of the control cartilage pellets at day 7. The increased
collagen II matrix staining by day 14 suggested that a wave of dif-
ferentiation occurred in the control cartilage pellet, beginning at
the periphery and progressing to the core. Increased levels of the
SOX9, collagen II and aggrecan in microwell-mesh tissues at day 7
were again consistent with an earlier induction of chondrogenic
signaling in the cartilage microtissues (Fig. 5). Taken together, the
GAG analysis, collagen II staining and gene expression data cumu-
latively suggest that the cartilage microtissues matured more
rapidly and in a more uniform manner than control cartilage pel-
lets. The caveat of accelerated chondrogenic induction in cartilage
microtissues, however, is an accelerated onset of hypertrophic
features. RUNX2 and collagen X, bothmarkers of hypertrophy, were
expressed at greater levels in the microtissues when compared to
the control cartilage pellets (Fig. 5). The only exception was RUNX2
at day 7, in which no difference was observed. Collagen I levels also
suggested a propensity for cartilagemicrotissues to produce a more
ﬁbrous cartilage or to progress towards bone-like tissue, a less
desirable trait in repair cartilage [11].
Filling defects with cartilage spheroids is a promising clinical
strategy. Co.donAG (Germany) is currently evaluating the use ofarticular chondrocyte-derived pellets to repair cartilage defects in
clinical trials [29]. We found that smaller diameter cartilage
microtissues were able to more efﬁciently ﬁll our cartilage defect
model than larger control pellets (Fig. 7), as smaller packing ma-
terial enables more efﬁcient ﬁlling and reduced void space. Un-
fortunately, mineralization and hypertrophy remained the primary
obstacles, as cartilage-like matrix, including GAG and proteoglycan,
were restricted to the cores of individual pellets. Both control pel-
lets andmicrotissues appeared to have a halo of hypertrophic tissue
around the outside of the tissue. In this case the greater dimensions
of the pellet cultures appeared enable the maintenance of larger
tissue cores that retained detectable GAG and proteoglycan content
(Fig. 7). The microtissues bonded strongly with the underlying
bone, but poorly to the native cartilage that formed the walls of the
defect model. The poor integration of both the pellets and the
microtissues with the native cartilage was unsurprising given that
the processing (ethanol sterilization and freezing) of the tissue to
produce the defect is unlikely to leave viable tissue. Nevertheless,
the poor integration between the pellets themselves remains
problematic, and reﬂects the propensity for MSC-derived tissues to
produce a calciﬁed tissue, rather than a uniform matrix with
cartilage-like properties. In recent work, we demonstrated that
microtissues formed from articular chondrocytes readily amal-
gamated into a continuous macrotissue in vitro [8]. In order for
MSC-differentiated cartilage tissues to progress into the clinic,
Fig. 6. GAG and collagen staining of cartilage tissues from the microwell-mesh and control pellet cultures. Tissues were counterstained for nuclei visualization with Nuclear Fast Red
for Alcian blue stain and DAPI (blue) for immunoﬂuorescent imaging of the collagens. Scale bars ¼ 250 mm.
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Fig. 7. Cartilage defect models were ﬁlled with either control cartilage pellets or microwell-mesh cartilage tissues, sealed with ﬁbrin glue and subcutaneously implanted into NOD/
SCID mice. Explant cartilage defect models were decalciﬁed, sectioned and stained for proteoglycan content (Safranin-O), GAG content (Alcian blue), evidence of chondrogenesis
(collagen II) and formation of ﬁbrocartilage or bone (collagen I).
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achieved.
Unfortunately, generating cartilage-like tissue from MSC re-
mains challenging, with no current protocol capable of generating
functional articular hyaline cartilage and chondrocytes that do not
exhibit a hypertrophic phenotype [11]. We reasoned that the large-
diameter control pellet cultures provide low-resolution heteroge-
neous readouts, confound efforts to optimize in vitro chondrogenic
protocols, and make it difﬁcult to characterize chondrogenic dif-
ferentiation kinetics. We show here that microtissues generate a
muchmore homogenous tissue in the ﬁrst week of culture, and that
the chondrogenic differentiation kinetics are likely more rapid than
could be interpreted from control pellet culture data. It is therefore
likely that themore homogenousmicrotissues will provide a higher
resolution readout of MSC differentiation kinetics. In previous
studies, control pellet cultures were exposed to chondrogenic in-
duction medium for 14e21 days, followed by medium supple-
mented with parathyroid hormone-like peptide to mitigate
hypertrophy [30,31]. The selection of the 14e21 day time points
reﬂect assumed peaks in chondrogenic gene expression and the
onset of hypertrophic features. Our data suggest that day 14 may
represent a key inﬂection point in control pellet cultures (Fig. 5), at
which intervention to block hypertrophic processes might be
effective. However, the microtissue GAG secretion proﬁles
(Fig. 4B&C), histological immunohistochemistry (Fig. 6), and gene
expression analysis (Fig. 5) suggest that chondrogenesis may have
peaked earlier, and that mitigation of hypertrophic onset may be
required as early as at day 7. Early chondrogenesis and hypertrophy
were also evident at the periphery of the control pellets as early as
day 7 (Fig. 6), although not as clear as in cartilage microtissues at
the same time point. The heterogeneity and delay in tissue matu-
ration within the core of the control pellet (Fig. 6) confounded
quantiﬁcation of the differentiation kinetics by bulk gene expres-
sion (Fig. 5). We suggest that the bulk gene expression in the more
homogeneous microtissues better represents MSC differentiation
kinetics. The rapid differentiation kinetics observed in microtissues
are likely comparable to the differentiation kinetics observed in the
periphery of the control pellets. The more homogeneous micro-
tissues should ultimately enable superior characterization of MSCdifferentiation kinetics, and better direct the timing of effective
medium supplementation with parathyroid hormone-like peptide
or other factors that mitigate hypertrophy.
While we applied the microwell-mesh concept to the manu-
facture of cartilage microtissues, we anticipate that this platform
will have more general utility in 3D cell culture applications. This
system will be particularly useful for drug screening and body-on-
a-chip applications where 3D microtissues are increasingly viewed
as superior in vitro model systems [1,3]. As multiple medium ex-
changes are required to replicate ﬂuctuations in systemic drug
concentration with time, or sequential treatment with a series of
drugs, the microwell-mesh platform ensures replication of similar
cyclical events or sequential treatments without displacing
microtissues.
5. Conclusion
Microtissues are an increasingly favored in vitro tissue mimics
for drug testing, studying developmental processes, and
manufacturing building blocks for tissue engineering [3]. Herein,
we described the fabrication protocol of a novel microwell platform
using readily accessible materials and equipment; the microwell-
mesh. The microwell-mesh platform, which retained microtissues
within discrete microwells, enabled the efﬁcient manufacture and
retention of MSC-derived cartilage microtissues in discrete micro-
wells over a 21-day culture period that included multiple full-
volume media exchanges. Cartilage-like matrix formation was
more rapid and homogeneous in microtissues than in conventional
large diameter control cartilage pellets. The more homogenous
matrix formation observed in the cartilage microtissues may pro-
vide a high-resolution tool to optimize chondrogenic medium for-
mulations and the culture conditions necessary to mitigate
hypertrophy and generate hyaline cartilage. Retention of the
microtissues within discrete microwells make the microwell-mesh
platform an ideal tool for the high-throughput optimization of
cartilage microtissue culture conditions. While we focused on
manufacturing cartilage microtissues, we anticipate that the
microwell-mesh platform will have broader utility in the manu-
facture of other tissue mimics and cancer models.
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